Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Clinical Trial Samples & Registry Study Purchase by Year
Clinical Trial Samples & Registry Study Purchase Obligations ($M) ($M)
Natera Clinical Trial Samples & Registry Study Purchase: $1.30M in FY2025, down 90.0% from a year earlier.
Latest, FY2025
1.30
Period ended Dec 31, 2025
Change on a year earlier
-90.0%
13 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (2026-02-27) ↗
Reported in Form 10-K/10-Q Note — Commitments & Contingencies (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Clinical Trial Samples & Registry Study Purchase Obligations ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.30 | -90.0% | Form 10-K (2026-02-27) ↗ |
| FY2024 | Dec 31, 2024 | 13 | – | Form 10-K (2025-02-28) ↗ |
Cite this data
StockData. (2026). Natera Clinical Trial Samples & Registry Study Purchase ($M), annual FY2024–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/purchase-oblig-clinical-samples
See every metric in the Natera KPI table. Data updated Nov 2, 2026.